Troksevazin caps. 300mg 100 pcs

Description

Composition
Active substance:
1 capsule contains: 300 mg troxerutin.
Excipients:
Lactose monohydrate 47 mg Magnesium stearate 3 mg.
capsule shell: Capsule body – dye quinoline yellow (E 104) 0.9%, dye sunset yellow (E 110) 0.039% titanium dioxide (E 171) 3%, and 100% gelatin; capsule cap – dye quinoline yellow (E 104) 0.9%, dye sunset yellow (E 110) 0.039% titanium dioxide (E 171) 3%, and 100% gelatin.
Description:
Solid cylindrical gelatin capsule № 1, housing – yellow, cap – yellow. The contents of the capsule: Powder from yellow to yellow-green in color, it may be the presence of conglomerates, which are pressure-sensitive split.
Product form:
Capsules 300 mg.
10 capsules in blister PVC / Al foil, or PVC / PVDC / Al foil.
5 or 10 blisters together with instructions for use in a cardboard package.
Contraindications
Hypersensitivity to rutoside or to other components of the formulation. Pregnancy (I term). Gastric ulcer and duodenal ulcer, chronic gastritis exacerbation, children under three years of age (a solid dosage form).
Caution should be used (long term use) in patients with renal insufficiency, children from 3 to 15 years (see. Section “Special Instructions”).
Indications
Chronic venous insufficiency, postflebitichesky syndrome, trophic disorders of varicose and trophic ulcers. As adjuvant treatment after sclerotherapy of veins and removal varices.
Hemorrhoids (pain, exudation, itching and bleeding).
Venous insufficiency and hemorrhoids during pregnancy, starting with the II trimester.
As an auxiliary treatment of retinopathy in patients with diabetes, hypertension and atherosclerosis.
Interaction with other drugs
The action is enhanced by simultaneous administration of ascorbic acid.
Overdose
In case of overdose may cause the following symptoms: agitation, nausea, headache, flushing. In case of overdose patients should wash the stomach, take activated charcoal, start symptomatic treatment if necessary.
pharmachologic effect
Pharmacological group:
Venotoniziruyuschee and venoprotektornoe means.
Pharmacological properties:
Angioprotective agent acts predominantly on the capillaries and veins.
Reduces voids between the endothelial cells by modifying a fibrous matrix disposed between the endothelial cells.
Inhibits aggregation and increases the degree of deformation of erythrocytes; anti-inflammatory effect.
In chronic venous insufficiency Troxevasin * reduces the severity of edema, pain, cramps, trophic disorders, varicose ulcers. Alleviates the symptoms associated with hemorrhoids – pain, itching and bleeding.
Due troksevazin beneficial effect on the permeability of the capillary walls resistance and it helps to slow down the development of diabetic retinopathy. Furthermore, its effect on the rheological properties of the blood helps prevent mikrotromboza retinal vessels.
Pharmacokinetics:
After oral absorption is about 10 -15%. Maximum plasma concentration achieved after an average of 2 hours after administration, the therapeutic plasma level is maintained for 8 hours. It is metabolized in the liver, partly excreted unchanged in the urine (20-22% of the dose) and bile (60-70% of the dose).
Pregnancy and breast-feeding
Troxevasin to use during pregnancy (II and III trimester) and lactation should be when the expected benefits to the mother prevails over the possible risk to the fetus and child.
Conditions of supply of pharmacies
Without recipe.
side effects
Allergic reactions (eg skin rash), nausea, diarrhea, heartburn, headache, “tides” of blood to the face, erosive and ulcerative lesions of the gastrointestinal tract.
They quickly disappear after cessation of treatment.
special instructions
If during treatment the severity of the symptoms is not reduced, it is necessary to consult a doctor. The drug has no effect on motor and mental reactions, does not interfere with driving and operating machinery. Experience with the drug in children younger than 15 years is not enough, it requires care in its application.
Storage conditions
In a dry, dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children!.
Dosing and Administration
Inside, during a meal time; swallow capsules whole, drinking plenty of water. At the initial stage of treatment 1 capsule (300 mg) 3 times a day.
The effect usually develops within 2 weeks and then treatment is continued at the same dose or reduce to the minimum maintenance – 600 mg, or suspended (in this case the achieved effect persists for at least 4 weeks). The course of treatment is an average of 3 to 4 weeks, the need for longer treatment is determined individually.
In diabetic retinopathy naznachayut0.9 -1.8 g / day.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist